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Abstract: Macrocyclic chemistry has provided chemists with 
a wealth of molecular ‘hosts’. Ever since resurgence in the 
field during the 1970s and 1980s these hosts’ similarities to 
natural structures, such the active sites of enzymes, have 
been noted. Latterly there has been great interest in the 
recently reported pillar[n]arenes. As if to underline the 
importance of these compounds, exciting applications are 
starting to emerge, from electrochemical sensors to 
antimicrobial agents. Novel uses appear destined to have an  
impact on clinical conditions from Alzheimer’s disease to 
cancer treatment. In order to demonstrate the impact of 
pillar[n]arenes across the chemistry-biology interface this 
review will cover the current state of the art from biomimicry 
and analyte-specific detection to emerging clinical 
applications. Examples include pillar[n]arene-based ion 
channels, enzyme-responsive compounds, imaging agents, 
biofilm inhibiting derivatives, drug complexing and drug 
releasing systems. 
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1. Introduction 
In the short time since the first paper on pillar[n]arenes was 
published
[1]
, this new family of macrocycles has found 
diverse applications across the sciences. One area of interest 
is the interface between chemistry and biology from 
biomimicry to diagnostics and therapeutics. Many excellent 
reviews on pillar[n]arenes are available
[2]
 but this review 
seeks to encompass those aspects of pillar[n]arene research 
which impact on biology, medicines and healthcare.  
 
 
Figure 1. Key pillar[n]arene derivatives 1 - 5. 
Although many derivatives appear in the following pages, it 
is fortuitous that most key compounds can be accessed from 
Ogoshi’s 1,4-dimethoxypillar[5]arene (1) via demethylation 
to the perhydroxylated species (2) and subsequent alkylation 
(e.g. 3). Of particular note is the extensive use of 
carboxylatopillar[5]- and [6]arenes (4a and 5a) together 
with their sodium (4b and 5b) or ammonium (4c and 5c) 
salts, as shown in Figure 1. 
2. Biomimetic pillar[n]arenes 
2.1. Transmembrane channels 
The phospholipid bilayers that form the exterior membranes 
of prokaryotic and eukaryotic cells are pierced by proteins 
and aggregates of small molecules to allow the passive and 
active transport of chemical species, from simple hydrated 
ions and metabolites to nucleic acids and proteins. While 
crystal structures of transmembrane proteins, 
electrophysiological techniques and computer simulations 
have advanced our knowledge of how these systems 
function, synthetic analogues have also been valuable in 
aiding our understanding of transmembrane transport 
phenomena.
[3]
 With their well-defined macrocyclic annulus, 
pillar[n]arenes present rigid core which can be extended by 
O-alkylation to span phospholipid bilayers.
[4] 
 
The first indication that pillar[n]arenes had the potential 
to function as molecular channels came when Chen, Hou 
and colleagues published a trio of papers revealing how 
perhydroxypillar[5]arene (2), its ethyl ester (3) and other 
derivatives aligned themselves into tubes through which 
water molecules could pass.
[5] These ‘water wires’ were able 
to conduct protons in a similar manner to electrons in a 
conventional metallic wire. The initial observation, backed 
up by X-ray crystallography, indicated that pillar[5]arene 
dimers could conduct protons by spanning an artificial 
phospholipid bilayer comprised of 
phosphatidylethanolamine, phosphatidylcholine (PC), 
phosphatidylserine (PS) and cholesterol. The proposed 
mechanism requires two pillar[5]arene molecules to align 
for charge to conduct protons in a manner similar to the 
gramicidin class of helical peptides. To give greater 
permanence to these channels, pairs of pillar[5]arenes were 
connected by alkyl chains  of four to eight carbons through 
ester or amide links e.g. 6. The optimum chain length for 
ester or amide dimers was found to be six carbons with the 
shortest and longest linkers imparting no channel activity. 
Conductivity occurred between pH 4.0 and 5.5 with the  [a] Peter J. Cragg 
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current increasing with decreasing pH consistent with a 
proton transfer mechanism. Addition of alkali metal cations 
had no effect except for Na
+
 which inhibited conductance 
through proposed complexation by the pillar[5]arene 
terminal ester groups. Figure 2 illustrates several examples 
of channel-forming derivatives. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Transmembrane channel-forming pillar[n]arene 
derivatives 6 – 10. 
The Hou group then prepared a number of pillar[5]- and 
[6]arene amides with tripeptide substituents (e.g. 7 and 8).
[6] 
The amide links can form complementary hydrogen bonds, 
in a manner reminiscent of β-sheets found in proteins, and 
the substituents extend the cavity to about 3.5 nm which 
approaches the thickness of natural phospholipid bilayers. 
Pillar[n]arenes with sequences of D- and L-Phe moieties 
terminating in carboxylic acids or ethyl esters were inserted 
into large unilamellar vesicles made from egg yolk L-α-PC 
(EYPC-LUVs) and loaded with 
13
C-labelled glycine. Both 
pillar[5]- and [6]arene with all-L-Phe substituents 
terminating in acid groups gave enhanced Gly transport 
through the vesicle membrane over passive diffusion. 
Similar experiments with L-Ala, L-Ser, L-Thr, L-Val, L-Leu 
and L-Phe demonstrated that all were transported by the 
pillar[6]arene derivatives, particularly those with the all-L 
sequence, whereas only Gly, L-Ala, L-Ser and L-Thr saw 
any enhanced transport by the smaller macrocycle. 
Transport activities were demonstrably higher for L-Phe 
over D-Phe when pillar[5]arene with all-L-Phe substituents 
was present in the vesicle.
[6a] 
Pillar[5]arene 7 was shown by 
Kumar and Hou to increase water permeability through 
vesicles formed from PC and PS.
[6b] 
Molecular dynamics 
suggested that arrays of macrocycles could aggregate and 
that this may change the morphology of the lipids by 
increasing the size of the vesicles until they became unstable 
and formed bilayers. As the pillar[n]arene derivatives could 
extend through the bilayer they can function as single 
channel conductors. This is evident from the current traces 
when the compounds were added to planar lipid bilayers 
which show clear ‘open’ and ‘closed’ states. Furthermore, 
transport rates were found to be similar to carbon nanotubes 
and only an order of magnitude lower than natural 
aquaporins. Other pillar[5]arenes with polypeptide 
substituents were found to have interesting biomimetic 
activity. The insertion of pillar[5]arenes with tripeptide 
substituents incorporating a single D- or L-Arg could be 
controlled by the voltage applied to EYPC-LUVs containing 
NaCl or KCl
[6c] 
and pillar[5]arenes incorporating L-Trp had 
antimicrobial activity against Gram-positive bacteria 
Staphylococcus epidermidis but not against Gram-negative 
Escherichia coli or rat erythrocytes.
[6d]
 
Xin, Dong and Chen appended two peptide sequences 
analogous to gramicidin A, along with shorter sequences 
such in 9, to a pillar[5]arene through click chemistry.
[7] 
In 
doing so they generated macrocycles capable of spanning a 
phospholipid bilayer. Experiments on EYPC-LUVs and 
planar bilayers comprised of 1,2-diphytanoyl-sn-glycero-3-
phosphocholine indicated enhanced H
+
 and K
+
 transport, 
respectively. The compounds’ biological activities were 
assessed against E. coli, Bacillus subtilis, Staphylococcus 
aureus and S. epidermidis and found to be less active against 
Gram-negative E. coli that the other Gram-negative bacteria. 
It was presumed that the mechanism of action was through 
membrane targeting and, for this reason, the compounds 
would have low haemolytic toxicity. Tests carried out on rat 
erythrocytes showed the compounds to have significantly 
lower haemolysis rates than gramicidin A. As with the 
gamicidins and the honeybee venom protein mellitin, these 
compounds undoubtedly form α-helices with the 
hydrophobic amino acid sidechains anchoring the 
pillar[5]arene in the phospholipid bilayer. 
Feng and Barboiu appended benzo-15-crown-ether-5-
ureido groups to a pillar[5]arene to give 10 with the 
intention that the crown ethers would complex and transport 
alkali metal cations.
[8] 
NMR data suggested the formation of 
dimers at concentrations of 12 mM. When the compound 
was incorporated in EYPC-LUVs, transport data showed 
selectivity for K
+
 and Rb
+
 over the other cations tested. 
While the formation of some type of channel was proposed, 
the authors could not discount a shuttling mechanism in 
which two crown groups formed a sandwich with the 
cations. 
Sun and Li approached the concept of ion-selective 
channels from a different angle. Having fabricated a 
nanopore in a polyimide membrane with an opening of 450 
nm and a tip of 16 nm, they linked the ionic liquid 1-(3-
aminopropyl)-3-methylimidazolium cation to the interior of 
the nanopore.
[9] 
The effect of this was to allow anions to 
pass through the nanopore. Subsequently 4a was added 
which bound to the imidazolium groups and reversed the 
selectivity towards cations. What made the system 
particularly interesting was that the effect could be reversed 
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by heating to 55ºC giving an analogue of a temperature 
sensitive ion channel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Enzyme-responsive and biomimetic pillar[n]arene 
derivatives 11 – 15. 
2.2. Enzyme-responsive and other biomimetic 
pillar[n]arenes 
Water-soluble pillar[n]arenes make excellent capping agents 
during metal nanoparticle synthesis as noted by the groups 
of Pérez-Juste and Pastoriza-Santos which used 11 to 
prepare 120 nm gold nanoparticles (AuNPs).
[10]
 Park, Moon, 
Kim and colleagues applied a similar method when using 5a 
to generate AuNPs which, in the presence of silver cations, 
exhibited greater peroxidase-like activity than their citrate-
stabilized analogues.
[11] 
As with better known capping 
agents such as citrate, it is presumed that the pillar[6]arene’s 
carboxylate groups spread out to cover the surface of the 
growing AuNPs until coverage is complete and growth 
ceases. Yu and colleagues prepared nanoparticles and 
nanosheets from 4a and acetylcholine with an appended 
pyrene substituent.
[12] 
Addition of acetylcholine esterase 
(AChE) cleaved the pyrene group leading to the formation 
of nanoribbons. Introduction of HAuCl4 and NaBH4 to the 
nanoparticles or nanosheets generated hybrid materials 
incorporating 6 nm AuNPs which grew on the addition of 
AChE. The hybrids were then used to catalyse the 
borohydride reduction of 4-nitroaniline to 1,4-
diaminobenzene. In another example of enzyme responsive 
morphology, Zhou and Diao prepared micelles from 13.
[13]
 
Their formation reflects the surfactant-like structure of the 
co-pillar[6]arene where the macrocycle is decorated with 
charged species and able to interact with water whereas the 
C18 substituent promotes micellar aggregation through 
hydrophobic effects. Hydrodynamic diameter measurements 
of 5 nm were consistent with two molecules meeting tail-to-
tail in a micelle. Subsequent addition of adenosine 
triphosphate (ATP) transformed the micelles into vesicles 
which increased in diameter to 150 nm which was reversed 
on addition of alkaline phosphatase. In addition, the vesicles 
could be loaded with calcein which responded to alkaline 
phosphatase by triggering its release. The Liu group used an 
enzyme-responsive pillar[5]arene to form a self-healing 
polymer.
[14] 
A pillar[5]arene ester coupled to an aldehyde-
functionalized PEG4000, 14, was shown to form a crosslinked 
hydrogel but to introduce self-healing functionality glucose 
oxidase and catalase were added to the gel scaffold. 
Addition of glucose to a cut in the gel resulted in reaction 
with glucose oxidase and a reduction in pH which reformed 
the aldimine with the concomitant release of hydrogen 
peroxide ameliorated by catalase. Sun and Yen used the 
displacement of acridine orange from 5a by choline to 
indicate the neurotransmitter’s presence and showed that 
when choline oxidase was added it reacted to form glycine 
betaine and fluorescence was switched off.
[15]
 
The Wang group has investigated another area of 
biomimicry: light harvesting.
[16] 
A BODIPY-bridged 
pillar[5]arene dimer, 15, and two BODIPY derivative guests 
combined to form highly stable supramolecular polymers 
that exhibited very strong absorption from 300 to 700 nm 
and, with energy transfer efficiencies up to 63%, represent 
one the best light harvesting models currently available. 
Harnessing the enzyme-like and enzyme-responsive 
behaviour pillar[n]arene-based materials, such as those 
shown in Figure 3, will have clear impacts in areas such as 
stereoselective synthesis and sensor technology. 
3. Pillar[n]arenes for detection 
3.1. Imaging 
The ability to functionalise pillar[n]arenes with a wide 
variety of substituents whilst keeping their inclusion 
properties almost unchanged was recognised by Stoddart as 
a route to molecular recognition and signalling.
[17] 
Incorporating a single pyrene group to a methylated 
pillar[5]arene allowed 16 (Figure 4) to signal guest inclusion 
by quenching fluorescence through photoinduced electron 
transfer. The guests in question, alkylamines, 
alkanediamines and polyamines, could be detected at 
concentrations below 100 μM using 57 μM solutions of the 
pillar[5]arene in a 1:1 acetonitrile-water solution. 
Association constants of diaminoalkanes with three to eight 
carbon atoms were between 1.0 x 10
4
 M
-1
 and 3.6 x 10
4
 M
-1
 
with ocylamine, spermine and spermidine all falling in the 
same range. Only n-hexylamine, with an association 
constant of 0.3 x 10
4
 M
-1
 was significantly outside this 
range. 
The Cohen group demonstrated that aqueous solutions of 
4c could encapsulate n-hexane diffused into the solution.
[18] 
Subsequent bubbling of xenon gas led to the formation of an 
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inclusion complex involving one hexane molecule and one 
hydrophobic xenon atom as determined by 
1
H and 
129
Xe 
NMR. This suggests a route by which biomarkers containing 
xenon may be prepared. 
 
 
Figure 4. Pillar[n]arenes 16 – 25 for imaging. 
Zhao and colleagues prepared vesicles from amphiphilic 
symmetric and asymmetric pillar[5]arenes 17 to 20, shown 
in Figure 4.
[19] 
Triethylene glycol or diethylene glycol 
monomethylether substituents, attached by click chemistry, 
facilitated vesicle formation in the presence or absence of 
rhodamine B, fluorescein isothiocyanate and a water-soluble 
viologen derivative. All the amphiphilic pillar[5]arenes were 
able to deliver rhodamine B but only asymmetric 
pillar[5]arenes could deliver the more hydrophobic 
fluorescein which enabled dual imaging of cells. Assays on 
immortalised cervical cancer HeLa cells indicated 
biocompatibility of the micelles formed from the 
pillar[5]arenes, however, they were also able to deliver 
doxorubicin (DOX) which was observed in both the  
cytoplasm and the nucleus. 
The Xue group used 4a as the capping agents of 
spherical silver nanoparticles (AgNPs) which were 18.7 ± 
2.18 nm in diameter.
[20] 
The AgNPs were stable and 
monodispersed in water so, given the pillar[5]arenes’ 
propensity to bind amines and diamines, the effect of seven 
di- and polyamines was investigated. While some change in 
colour was observed for ursol, ethanediamine, 1,12-
dodecylamine or 1,6-hexamethylenediamine, addition of the 
polyamines spermine, tetraethylenepentamine and 
triethylenetetramine resulted in a black precipitate. The 
authors proposed that this effect could be used to detect 
ultralow concentrations of polyamines by surface-enhanced 
Raman spectroscopy. The same group prepared AgNPs with 
water-soluble pillar[5]- or [6]arene with imidazolium 
substituents as capping agents.
[21] 
Following the addition of 
aqueous amino acid 10
-3
 M solutions (Lys, Arg, His, Gly, 
Glu, Tyr, Asp, and Thr) only glutamatic acid elicited a red 
to yellow colorimetric response.  
The Huang group prepared two cruciform species with 
either ethylpyridinium or naphthyl termini.
[22] 
These stacked 
to form nanorods of charge transfer complexes, however, the 
cationic compound could act as the core of a supramolecule 
upon the addition of four equivalents of 21. Administration 
of this complex together with the naphthyl species to MCF 
cells led to dethreading of the ethylpyridinium derivative 
and nanorod formation and blue fluorescence in the 
cytoplasm. Fluorescence was not observed in non-cancerous 
HEK293 cells due to their relatively higher pH. The group 
followed this work with the synthesis of pillar[5]arene- 
DOX conjugate 22.
[23] 
An asymmetric rotaxane thread with a 
triphenylphosphine stopper linked to a 4-(4-(1,2,2-
triphenylvinyl)phenyl)pyridinium moiety by an alkyl spacer 
was linked through the pillar[5]arene to give a highly 
fluorescent rotaxane. The prodrug localised in the 
mitochondria of HeLa cells but not HEK293 cells, 
suggesting a method of delivering DOX to cancer cells 
whilst imaging drug delivery. The Yu group mixed 1-ethyl-
4-(4-(1,2,2-triphenylvinyl)phenyl)pyridinium bromide with 
23 to form a fluorescent complex.
[24]
 The complex 
assembled into spherical particles with an average diameter 
of 43 nm which were administered to HeLa cells. No 
significant cytotoxicity was found and the highly fluorescent 
complex localised in the cytoplasm. These fluorescent 
pillar[n]arenes are shown in Figure 4. 
The Li group prepared a hybrid material by grafting 24 
(Figure 4) onto graphene.
[25] 
Addition of the electron-
deficient dye safranine T led to the formation of an inclusion 
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complex with the surface-bound pillar[5]arenes which 
quenched 95% of the dye’s fluorescence through 
fluorescence resonance energy transfer with graphene. 
Safranine T could be displaced by paraquat, resulting in 
associated recovery of fluorescence, but not by 2,2’- or 4,4’-
bipyridine. Paraquat analogues diallyl-4,4'-bipyridine and 
dibutyl-4,4'-bipyridine also had no effects. HeLa cells 
incubated with the graphene complex exhibited minimal 
fluorescence whereas safranine T alone or addition of 
paraquat to the complex, followed by extensive washing 
with phosphate buffered saline, fluoresced red. No acute 
cytotoxicity was found for the complex so it was 
administered subcutaneously to mice which were 
subsequently treated with paraquat or its two alkyl 
analogues. Fluorescence recovery was only observed in the 
first case making this a very selective in vivo test for 
paraquat. 
Zhao, Tang, Li and colleagues grafted 25 (Figure 4) onto 
graphene oxide.
[26] 
Treatment with acridine orange gave a 
complex in which the dye’s fluorescence was quenched by 
90%. It was unaffected by uric acid, dopamine, tyrosine, 4-
nitrophenol, 4-aminophenol, hydroquinone, ascorbic acid, 
simple salts or sugars, with only acetaminophen able to 
regenerate fluorescence.   
A displacement assay for ATP based on the 12-Dapoxyl 
sodium sulfonate complex was developed by the Bitter 
group.
[27] 
Enhanced fluorescence and a hypsochromic 
spectral shift was observed upon the addition of Dapoxyl 
sodium sulfonate which was ascribed to strong, yet partial, 
inclusion. Fluorescence quenching induced by ATP was an 
order of magnitude greater than that by its mono- and 
diphosphate homologues or guanosine-5′-triphosphate. 
 
3.2. Electrochemical detection 
The ability for guest inclusion to be monitored by 
electrochemical methods, particularly where that guest is a 
charged species, has long been utilised as a method of 
detection.
[28] 
Use of the pillar[n]arenes as molecular 
receptors in electrochemical systems is starting to yield 
some interesting results. 
 
Figure 5. Pillar[n]arenes 26 – 29 for electrochemical detection. 
Cragg and colleagues used Ogoshi’s original 
dimethoxypillar[5]arene, 1, as a modifier in carbon paste 
electrodes to detect alkali metal cations.
[29]
 Thermodynamic 
simulations suggested that only Na
+
 and K
+
 would bind to 
the pillar[5]arene and give a response. Capacitive responses 
towards alkaline metal salts on composite sensors confirmed 
this selectivity. Na
+
 could be monitored in the 4 x 10
-2
 to 0.2 
M range and a limit of detection of 4.1 x 10
-2
 M. This was 
within the clinical range for the analyte whereas for K
+
, 
while the sensitivity was slightly greater, the limit of 
detection was 2.28 x 10
-3
 M and above the lowest 
physiological concentration encountered. Similar selectivity 
was observed spectroscopically for pyrrolidino- and 
morpholinopillar[5]arene derivatives 26 and 27 (Figure 5) 
reported by Stoikov and colleagues, although greatest 
selectivity was for Li
+
.
[30]
 Following the discovery by Chen, 
Hou and colleagues
 
that 3 could form ‘water wires’,[5] Cragg 
and colleagues incorporated the macrocycle in an ion-
selective electrode and measured the change in potential 
from pH 1 to 4.
[31] 
The response time after each addition was 
pH independent suggesting that the rate limiting step was 
due to the addition and loss of protons on the electrode. 
Other groups investigated the effects on electrodes of 
surface modification by pillar[n]arenes. The Diao group 
prepared composite materials from 25 onto graphene 
oxide.
[32] 
The modified graphene oxide was capped with 
AuNPs and solutions of the ternary composite deposited on 
glassy carbon electrodes (GCEs) which gave an excellent 
response to dopamine with a linear range of 1.5 × 10
-8
 to 1.9 
× 10
-5
 M and detection limit of 1.2 × 10
-8
 M. Evtugyn and 
colleagues modified GCEs directly with 2 and demonstrated 
that the macrocycles achieve about 60% oxidation to the 
quinone and hydroquinone forms.
[33] 
Addition of Ag
+
 and 
Cu
2+
 ions generated AgNPs and Cu2O particles, 
respectively. The group prepared an AChE biosensor from 
their GCE incorporating 2 by treating it with N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide chloride 
followed by N-hydroxysuccinimide and finally AChE in 
phosphate buffered saline.
[34] 
The addition of the 
pillar[5]arene gave an enhanced electrode response to sub-
nanomolar concentrations of the anticholinesterase 
pesticides malaoxon,  methylparaoxon, carbofuran and 
aldicarb over five orders of magnitude. A further example of 
a modified GCE from Evtugyn and colleagues involved 
deposition of carbon black onto the electrode surface prior 
to a coating of 2.
[35] 
Cyclic voltammetry was used to detect 
weak organic acids (oxalic, succinic, glycolic and acetic) 
and DNA from chicken erythrocytes, fish and salmon 
sperm. Interestingly, the method was able to differentiate 
between native DNA and that exposed to reactive oxygen 
species, sulfamethoxazole and DOX. 
The groups of Hianik and Evtugyn developed 
aptasensors for cytochrome c from GCEs with layers of 
electropolymerized neutral red, 4a terminated with neutral 
red and a DNA aptamer specific to cytochrome c.
[36] 
The 
exact number of dye molecules attached by EDC/NHS 
coupling was not determined, however, cytochrome c was 
identifiable from 1 x 10
-9
 M to 1 x 10
-3
 M even in the 
presence of 1000-fold excesses of albumin, polyethylene 
glycol and lysozyme. 
Liao, He and colleagues developed an electrochemical 
sensor to detect the breast cancer susceptibility gene 
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BRCA.
[37] 
Pillar[5]arene 28 (Figure 5) was immobilised on a 
gold electrode before addition of DNA with an alkylamino-
modified terminus that threaded through the macrocycles. 
Hybridization of BRCA target DNA with methylene blue-
labelled signal DNA allowed it to bind, in turn, with the 
DNA-modified electrode surface. The differential pulse 
voltammetry signal decreased logarithmically in the range of 
3.3 × 10
-9
 M to 3.3 × 10
-5
 M with a detection limit of 1 × 10
-
9
 M making it of clinical utility. 
Cragg and colleagues attached 29 (Figure 5) directly to 
gold electrodes through dithiol links and demonstrated 
selectivity for Li
+
 over other alkali metals with binding 
decreasing with increasing ionic radii.
[38] 
This differs from 
the group’s observation of selectivity for Na+ and K+ with 1, 
however, when immobilised in carbon paste that macrocycle 
is unable to rotate around its methylene bridges and cannot 
adopt a suitable coordination environment for Li
+
. When 
attached to the gold surface through thiols on one ring the 
remaining rings can rotate to bind partially dehydrated Li
+
 in 
a tetrahedral or octahedral environment in agreement with 
the findings of Stoikov.
[30]
 The group used the same 
pillar[5]arene derivative to target the biogenic amines 
putrescine, spermidine and spermine.
[39] 
The faradaic 
response depended on both the number of amine groups and 
the carbon chain length of the biogenic amine which 
allowed discrimination between the three.  
 
3.3. DNA and protein recognition 
The cavities of pillar[n]arenes are well known to bind small 
molecules with terminal amines which make them naturally 
complementary to many amino acid sidechains and the N-
terminus of proteins. Similarly, it is possible to quaternarise 
pillar[n]arenes with ammonium, imidazolium or similar 
termini as shown in Figure 6, thus making them attractive to 
the anionic phosphate backbone of DNA or protein 
carboxylic acids.   
The Li group used the threading properties of 
pillar[n]arenes to mask adipic acid linked to amino silane-
modified silicon wafers.
[40]
 Addition of 30 formed 
pseudorotaxanes with the adipic acid which could be 
observed by changes in surface contact angle upon changes 
in pH. Bovine serum albumin (BSA) bound to the surface 
when the pseudorotaxanes were present at pH 3 but not at 
pH 11 when the pillar[5]arenes no longer bound to adipic 
acid. It was hypothesised that hydrophobic effects were the 
driving forces that made BSA and the pillar[5]arenes 
interact and that, when the pillar[5]arene was no longer 
attracted to the functionalised silicon surface, BSA remained 
in solution. 
The Bitter group developed a fluorescence indicator 
displacement assay based on non-fluorescent complexes 
formed between 4a and 4-amino-1,8-naphthalimide 
derivatives with N-butylamine or N-(3-methylimidazol)ethyl 
substituents.
[41] 
Of 19 common amino acids tested only 
lysine and arginine were able to elicit any fluorescence 
regeneration with the latter displacing more of the 
fluorescent dye. By contrast, the polyamine cadaverine was 
able to displace almost all of the dye. Another linear 
biogenic amine, putrescine, was ineffective which reflects 
the differences in binding affinities determined by 
Stoddart.
[17]
 
Wei, Lin and colleagues used 31 as a highly selective 
and sensitive receptor for L-Trp with a limit of detection in 
the sub-micromolar region.
[42] 
A 90% quenching of 
fluorescence was observed when five equivalents of L-Trp 
were added. 
 
 
Figure 6. Pillar[n]arenes 30 – 33 for DNA and protein 
recognition. 
Duan and Lu determined the association constants of 
complexes between 32 and 20 natural amino acids, several 
short chain dicarboxylic acids and glutathione.
[43] 
Only 
glutathione, glutamic acid and aspartic acid exhibited strong 
binding, with Ka values of about 1 x 10
6
 for all three, which 
was two orders of magnitude greater than the other analytes 
tested. 
DNA transfection applications have been explored using 
cationic pillar[n]arenes. Nierengarten, Remy and colleagues 
prepared dendrimeric pillar[5]arenes 33a and 33b using 
click chemistry to attach the benzyloxycarbonyl-protected 
dendrons.
[44] 
Treatment with excess trifluoroacetic acid gave 
the water soluble ammonium derivatives as their triflate 
salts which formed aggregates at concentrations above 3 
nM. Both pillar[5]arenes were shown to bind plasmid DNA 
by gel electrophoresis and transfection experiments 
demonstrated that the complex can deliver DNA into HeLa 
cells. Transfection efficiencies, determined by a luciferase 
assay, were slightly lower than that of the standard 
transfection agent, polyethylenimine, but were also less 
cytotoxic. 
The Junquera group adopted a different approach to 
transfection by incorporating 11 in lipoplexes composed of 
the sodium salt of 1,2-dioleoyl-sn-glycero-3-phospho-(1′-
rac-glycerol)) and zwitterionic 1,2-dioleoyl-sn-glycero-3-
phosphatidylethanolamine.
[45] 
The cationic pillar[5]arenes 
facilitated the formation of lipoplexes from the anionic 
lipids and anionic plasmid DNA more successfully than 
simple metal cations. A DNA protection assay was used to 
demonstrate lipoplex stability against DNAse 1 degradation 
and experiments on monkey kidney (COS-7) cells showed 
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cell viability comparable to commercial transfection agents 
and 80 to 95% transfection. 
4. Medical applications 
4.1. Drug complexation 
Macrocycles with hydrophobic cavities, particularly the 
cyclodextrins
[46]
 and cucurbiturils
[47]
, have been used to 
form inclusion complexes with numerous drug molecules to 
enhance their solubility and consequent bioavailability. The 
potential for pillar[n]arenes to act in this regard was first 
made clear from the X-ray structure of the 4a·tetracaine 
complex published by Danylyuk and Sashuk.
[48] 
Noting that 
4a had limited aqueous solubility, they dissolved it in an 
ethanol-water mixture. Inclusion of water, seen with 3, was 
not observed in the crystal structure, as two ethanol 
molecules filled each macrocyclic cavity. Addition of the 
potent anaesthetic tetracaine to 4a in ethanol-water solution 
resulted in crystals which revealed two binding modes. Each 
macrocycle held one tetracaine molecule with a second 
positioned between pairs of pillar[5]arenes to give a 2:3 
host:guest stoichiometry (Figure 7). A range of drug 
molecules bound by pillar[n]arenes is shown in Figure 8. 
 
 
 
 
 
 
 
 
Figure 7. X-Ray structure of 4a·tetracaine 
Wheate and coworkers undertook a larger study of 
pillar[n]arene-drug complexation using NMR and molecular 
modelling to infer complexation.
[49] 
Salts 4c, 5c and their 
pillar[7]arene analogue were used as excipients for 
memantine, used to treat Alzheimer’s disease, the antiseptic 
chlorhexidine, the disinfectant proflavine and its derivative, 
acridine orange. In each case NMR evidence indicated 
inclusion of the drug molecule by the larger pillar[n]arenes 
although modelling indicated some binding affinity even by 
the pillar[5]arene. Other pharmaceutically important 
compounds such as the antiparasitic drug albendazole and 
N-acetyl-L-phenylalanine, found in the urine of patients with 
the genetic condition phenylketonuria, were found not to 
exhibit NMR shifts consistent with inclusion. This is despite 
both having the potential to bind though a combination of 
hydrogen bonding and hydrophobic effects and the known 
complexation of albendazole by cyclodextrins and 
cucurbiturils. Investigation of proflavine fluorescence 
quenching indicates endo- or exo-cavity complexation 
occurs with increasing concentrations of pillar[n]arene 
which supports inclusion and is also reminiscent of the 
crystal structure of the tetracaine complex. In vitro assays 
demonstrated that both the pillar[6]- and [7]arene 
derivatives were nontoxic but that 5a inhibited proliferation 
of human embryonic kidney cells (HEK293) above 25 μM 
and human ovarian carcinoma cells (OVCAR3) above 250 
μM. Growth of the latter were also inhibited by its 
pillar[7]arene analogue but at 100 μM. 
Pisagatti and Notti reported that 4c bound the powerful 
antibiotic amikacin disulfate.
[50] 
To maximise the efficacy of 
the drug while minimising nephrotoxic and ototoxic side 
effects it needs to be directed at the microenvironment 
where it is required. At a 2:1 ratio of drug to carrier, 
inhibition of S. aureus growth was equal to that of the drug 
alone over 8 hours. Strong complexation (Kass = 9.9 ± 1.28 × 
10
3
 M
-1
) under physiological conditions suggests that the 
complex may be a route to better drug targeting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Drug molecules complexed by pillar[n]arenes. 
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Pillar[6]arene 5a was found to bind the anticancer drug 
oxaliplatin effectively. A report from the groups of Sessler, 
Meng and Li detailed the pH-selective dissociation of the 
drug from the macrocycle with an association constant 24 
times higher at pH 7.4 than at 5.4.
[51] 
Complexation 
increased the drug’s stability in plasma almost threefold and, 
significantly, did not reduce its efficacy against the HepG-2, 
MCF-7 and A549 cancer cell lines in in vitro tests. In vivo 
effects on tumour growth were evaluated in xenograft 
Chinese Kun Ming (KM) mice bearing S180 (murine 
Sarcoma) tumours and showed that at doses of 35 mgkg
-1
 
the complex was more effective than the drug alone. Acute 
toxicity studies revealed that the complex was no more toxic 
than the drug itself and therefore encapsulation provides a 
safe way to enhance the anticancer properties of oxaliplatin. 
Cui and coworkers found that the 5a binds sanguinarine, 
a poorly water-soluble alkaloid with activity against bacteria 
and inflammation, and increases its aqueous solubility 
fourfold.
[52] 
The complex formed at pH 7.4 and had a Kass = 
2.4 ± 0.3 × 10
5
 M
-1
.The drug is effective against bacteria in 
its cationic form and complexation shifts its effective pKa 
from 8.3 to 10.3 thus increasing its activity. Antimicrobial 
assays using S. aureus and E. coli showed a twofold 
increase in activity against both the Gram-positive and 
Gram-negative bacteria in serial dilution experiments 
whereas no changes were observed for 5a alone even when 
in tenfold excess. 
Yu and Ma reported that the sparingly soluble, yet 
potent, anticancer agent 20-(S)-camptothecin (CPT) is also 
complexed by 5b.
[53] 
Both CPT and its derivative 10-
hydroxycamptothecin (HCPT) were bound by the 
pillar[6]arene in what appear to be 2:1 host: guest 
complexes. Drug solubilities increased from low micromolar 
to 1.9 mM and 1.2 mM for CPT and HCPT, respectively, 
which made them soluble enough for intravenous injection. 
Tests on HeLa cells found that the complexes had lower IC50 
values than for the drugs alone. These combined findings 
suggest that complexes of 5b and 5c with CPT or HCPT 
have the potential for intravenous administration at lower 
doses to deliver the same anticancer effects. 
A different approach to CPT solublisation was adopted 
by Hu and colleagues.
[54] 
Pillar[5]arene 34 was terminated 
with galactose substituents to bind CPT and impart water 
solubility. A prodrug was prepared from CPT linked via a 
disulfide bridge and triazole to an alkylammonium moiety. 
NMR indicated the formation of a 1:1 host:guest complex 
which aggregated into spheroids approximately 100 nm in 
diameter. Release of CPT from the nanoparticles was 
initiated by glutathione at concentrations between 2 and 10 
mM with up to 87% of CPT being released with 200 
minutes. Without glutathione, the nanoparticles were stable 
for at least a month under physiological conditions. 
One of the most important anticancer agents of recent 
years is tamoxifen, however, it has poor water solubility and 
consequently low bioactivity. The Huang group formed a 
1:1 inclusion complex between tamoxifen and 5c.
[55] 
Experiments on MCF-7 and HeLa cells comparing the host, 
tamoxifen and the complex found no adverse effects on cell 
viability over four hours but the complex reduced viability b 
60 to 75% over the same period. 
Venkataramanan and coworkers investigated the 
inclusion of the analgesic acetaminophen in 1 using 
computational and spectroscopic methods which indicate 
that a 1:1 complex is formed.
[56] 
Complexation could have 
value in ameliorating the effects of acetaminophen overdose, 
however, the insolubility of the pillar[5]arene makes it 
unsuitable for such a purpose. The results point at a potential 
for water-soluble pillar[5]arenes to remove an excess of the 
drug. 
 
4.2. Controlled drug release by micelles, vesicles and 
nanoparticles 
Many methods exist to facilitate the controlled release of 
drugs by supramolecular systems. Macrocycles can 
aggregate into vesicles or micelles, encapsulating the 
molecules to be released, but they may also form simple 
host-guest complexes with release triggered by a change in 
environment. Finally, loaded macrocycles can form part of a 
hybrid material and function as nanovalves to release 
cargoes of drugs. Several pillar[n]arenes, such as those in 
Figure 9, have been used for drug release. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Pillar[n]arenes 30 – 33 for drug release. 
Asymmetric pillar[n]arenes, in which the substituents in 
the para positions are non-identical, are predisposed to form 
structures such as bilayers, vesicles and micelles. In one of 
the earliest examples of micelle formation Sakurai and 
colleagues designed a pillar[5]arene with n-butyl and 
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propargyl substituents.
[57]
 Isolation of the D5 conformer and 
subsequent click reaction introduced N-propylaminolysine 
groups to give 35 which formed 4.5 nm micelles in water at 
pH 3. Based on small angle X-ray scattering and multi-angle 
light scattering experiments it was deduced that the 
pillar[5]arenes formed tail-to-tail dimers through 
hydrophobic forces and that the lysine groups wrap around 
this core to give the observed micelle-like properties. This 
example of stimulus-response aggregation would go on to 
feature in most drug delivery systems. 
The Xue group prepared 36, which formed micelles 85 
nm in diameter upon the addition of sodium 4-
(octadecyloxy)benzoate.
[58] 
The vesicles collapsed at pH 4 
providing a triggering mechanism for controlled release 
which was confirmed when the water-soluble fluorescent 
dye calcein, used as a drug model, could be detected when 
the pH of solutions containing calcein-containing vesicles 
was lowered. Hu and Wang reported a similar example of 
controlled release from vesicles using glutathione as the 
trigger.
[59] 
A lysine derivative, 2,6-diamino-N-(2-
mercaptoethyl)hexanamide, was linked to 9-(3,5-
dimethylphenoxy)nonane-1-thiol by a disulfide bridge, to 
allow cleavage by glutathione, and included within 4a. The 
complex formed spherical vesicles in the order of 100 nm in 
diameter which could be loaded with the broad spectrum 
anticancer drug metronidazole (MTZ). Addition of 
glutathione at pH 5 resulted in vesicle disaggregation and 
over 80% of the drug released within 45 minutes. A similar 
approach was adopted by the Wang group which found that 
the complex between 5a and the anticancer drug DOX 
linked to a polyether- or alkyl-N-pyridinium groups by a 
hydrazone moiety formed nanospheres at pH 7.
[60]
 When 
incubated in phosphate buffered saline at pH 7.4 release of 
DOX was less than 5% over nine hours whereas 85% of the 
drug was released over the same period at pH 5.5. Although 
free DOX was exhibited greater cytotoxicity than the 
complexes, the latter still displayed good dose responses to 
human ovarian cancer (SKOV3) cells, murine breast cancer 
(4T1) cells and HeLa cells. Delivery was not by the usual 
diffusion pathway but by nanoparticle endocytosis offering a 
route to administration which may circumvent drug 
resistance. Wang and colleagues also showed that 5a could 
form binary vesicles when complexed with N-1-decyl-
ferrocenylmethylamine.
[61]
 Complexation, if 1:1, led to 
asymmetry which was confirmed by NMR and UV-visible 
spectroscopy. The effects of inclusion on the ferrocenyl 
moiety were observed by cyclic voltammetry. Addition of 
the complex to a solution of pyrene resulted in fluorescence 
quenching concomitant with aggregation into vesicles. The 
same experiment with the sodium salt of the pillar[6]arene’s 
subunit, hydroquinone-O,O′-diacetic acid, induced no such 
changes. Dynamic light scattering experiments indicated the 
existence of structures 170 nm across which disassembled 
below pH 6. This suggested a potential therapeutic 
application as the microenvironment surrounding cancerous 
tumours tends to be below pH 7. MTZ was added to an 
aqueous solution of the pillar[6]arene complex to form 
vesicles about 700 nm in diameter which contained around 
11% of the drug which was shown to be released upon 
acidification of the solution. To test the effects in vitro, 
human hepatocarcinoma (SMMC-7721) cells were 
incubated with MTZ-loaded vesicles. The effects on cell 
viability were slightly better over 96 hours than for MTZ 
alone, however, in tests on murine fibroblast (NIH3T3) cells 
the MTZ-containing vesicles had significantly lower chronic 
toxicity than MTZ alone. The same researchers also used 
complexes of 5a with a pyridinium amphiphile to form 
vesicles which delivered DOX.
[62] 
Results of drug inclusion 
were similar for the studies involving MTZ: lower toxicity 
towards NIH3T3 cells but similar cytotoxicity against 
cancer cells, in this case the MCF-7 breast cancer cell line. 
Hu and colleagues used the same macrocycle to bind 
DOX attached to isonazide by a hydrazone bond.
[63] 
Fluorescence microscopy of SKOV3 cells incubated with 
the complex indicated hydrolysis and co-location of DOX 
with the lysosomes and nuclei.   
Xue, Shi and colleagues prepared a pseudorotaxane 
formed from 5a and azobenzene-terminated 1,5-
bis(hexyloxy)naphthalene.
[64] 
Vesicles formed from this 
complex were used to encapsulate DOX which could be 
released either at low pH, with over 90% release at pH 2, or 
by irradiation at 365 nm for 40 minutes to give over 80% 
release. The same approach was adopted by Zhang, Hu and 
colleagues who used the smaller 4a and a disubstituted 
naphthalimide with substituents incorporating disulfide 
bonds.
[65] 
Vesicles containing DOX were able to release the 
drug in response to the presence of glutathione and were 
significantly more effective against both human alveolar 
adenocarcinoma (A549) cells and HeLa cells than DOX 
alone. Tong, Jiang and colleagues prepared vesicles from 5a 
and poly(ε-caprolactone) with a terminal 4-((4-
methoxyphenyl)diazenyl)phenoxy group with a quaternary 
ammonium linker.
[66] 
The vesicles were loaded with DOX 
which was released in response to reducing the pH from 4.5 
to 3 or from irradiation at 365 nm. The drug-free vesicles 
had negligible effects on liver hepatocellular (HepG2) cell 
viability at concentrations up to 250 μg ml-1 but over 24 
hours the DOX-loaded vesicles reduced cell viability below 
60% at drug concentrations in excess of 20 μg ml-1. 
Jin and Ji prepared micelles from 4a and methyl 
viologen-functionalised DOX.
[67]
 It was anticipated that the 
extracellular pH conditions would cleave the thiol link 
between the drug and methyl viologen substituent. The 
micelles were shown to be toxic towards HepG2 cells at pH 
6 in a dose dependent manner with an IC50 value of 3.75 mg 
L
-1
. 
Pei and Pei synthesised 37 and prepared vesicles from its 
complex with a galactose derivative with an appended 
polyether and a pyridinium terminus.
[68] 
HepG2 and DOX-
resistant HepG2 (HepG2/ADR) cells were incubated with 
free DOX and DOX-loaded vesicles. Cell viability 
decreased significantly in the presence of both vesicle 
systems, however, DOX alone was much less cytotoxic 
towards the HepG2/ADR cells at all concentrations. The 
results indicate that the vesicles act through endocytosis and 
drug release and, by doing so, DOX avoids the pathway by 
which some HepG2 cells have become resistant. The same 
group used a combination of the functionalised galactose 
with 38 to prepare vesicles which disassembled only in the 
presence of both low pH and glutathione.
[69]
 Inclusion of 
DOX within the vesicles was possible at up to 85% loading 
which is significantly higher than other systems. Incubation 
with MCF-7 cells and non-cancerous HEK293T cells 
showed significantly greater cytotoxicity over 72 hours 
against the former and significantly better protection for the 
latter. 
Much of the controlled release research involving 
pillar[n]arenes has involved potential anticancer 
applications, however, the groups of Hu and Wang have 
developed a method to deliver insulin under hyperglycaemic 
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conditions.
[70] 
Addition of 4-borono-1-hexadecylpyridin-1-
ium bromide to 4a formed vesicles. Electron microscopy 
showed that the 130 nm vesicles grew to 320 nm particles 
with rough surfaces when fluorescently labelled insulin was 
added, suggesting that insulin molecules bound to surface 
cavities. Addition of D-glucose at a normal physiological 
concentration led to 20% insulin release after an hour but at 
five times the concentration about 70% of the insulin was 
released over the same time period. Release at pH 7.0 was 
more than double that at pH 7.4 over an hour making the 
controlled release highly pH sensitive. The insulin-loaded 
vesicles also displayed good cytocompatibility when added 
to lung fibroblast (MRC-5) cells. 
The Ji group developed a displacement assay for 
cysteine designed to work in the acidic microenvironment 
which surrounds tumours.
[71] 
Pillar[5]arene 4a formed a 
strong inclusion complex with a cysteine probe prepared 
from 1-(4-dimethylamino-phenyl)-ethanone and 4-
pyridinecarboxaldehyde, and subsequently quaternarised 
with iodomethane. The probe could not be displaced from 
the yellow complex by cysteine until the pH dropped below 
6 whereupon the probe was released and reacted with free 
cysteine to give a colourless solution. The group used an 
isomer of their cysteine probe, encapsulated within 39, as a 
temperature sensitive cysteine detector.
[72] 
When heated 
above its lower critical solution temperature decomplexation 
occurred leading to reaction between the probe and cysteine 
which was signalled by quenching the complexes orange 
colour. Tests on HeLa cells indicated the complex’s low 
cytotoxicity over 24 hours.  
The Yang group used the pillar[n]arenes’ controlled 
release properties by adsorbing 4a onto the surfaces of 
mesoporous silica nanoparticles (MSNs) previously 
modified to be covered with propylpyridinium groups.
[73] 
When the MSNs were loaded with rhodamine 6G, before 
being capped with 4a, the dye was released by acetylcholine 
proportional to the dose delivered. The group also 
investigated the properties of MSNs coated with a 
trimethylammonium-terminated propyl ester towards 
AuNPs capped with 4a.
[74] 
Filling the MSNs with rhodamine 
B prior to addition of the AuNPs allowed the system’s 
controlled release to be monitored. Release was initiated by 
heat or displacement of AuNPs when diaminoethane was 
added thus providing two potential triggers for drug release. 
Short linear diamines are well known to bind to 
pillar[5]arenes and, in this context, affected the solubility of 
the AuNPs. Composite MSNs have also been prepared by 
the Fu group which appended 1,6-(1-pyridiniumhexyl)-
hexanediamine groups from their surfaces and then formed 
pseudorotaxanes using 4a.
[75] 
The MSNs could be loaded 
with DOX prior to addition of the pillar[5]arenes and release 
of the drug triggered by low pH, high pH or high 
concentrations of Zn
2+
. Tests against human breast 
adenocarcinoma (MCF7) cells showed that unloaded MSNs 
were non-toxic but when delivering DOX cell viability 
decreased below 20% after 48 hours at 9.5 μg mL-1. This 
was slightly less cytotoxic than DOX alone but delivery was 
by an endocytosis pathway. 
Hu, Zhu, Wang and colleagues prepared poly(γ-benzyl-
L-glutamate)-based polymers which were then extended to 
give diaminobutyl termini.
[76] 
Addition of 4a led to the 
formation of pseudorotaxanes and aggregation into 
polymersomes which could be filled with MTZ. A 
copolymer which additionally incorporated biotin groups 
was designed to target biotin receptor-positive HeLa cells 
and degrade under the local low pH conditions to release 
MTZ. Tests on NIH3T3 cells showed lower cytotoxicity for 
both types of polymersome however MTZ toxicity towards 
HeLa cells was enhanced when delivered by the biotinylated 
polymersome. 
The Du group prepared 40 which, as the polyanion, 
formed pseudorotaxanes on the surface of MSNs filled with 
DOX and coated with quaternary ammonium or pyridinium 
groups.
[77] 
Cargo release was triggered by Zn
2+
, acidic 
conditions or paraquat. MSNs were also formed around gold 
nanorods which allowed photothermal effects from near 
infra-red radiation at 808 nm to release the drug. Irradiation 
caused no adverse effects on A549 cells but addition of the 
gold nanorod MSNs caused apoptosis. 
Wang and colleagues used 40 and 41 to construct binary 
micelles.
[78]
 The pillar[n]arenes bound to the head group of 
an pyridinium-modified N-decylnaphthalimide to form 
structures about 200 nm in diameter. DOX- and MTZ-
loaded micelles, which were much larger than the drug-free 
analogues, both performed slightly better than the drugs 
alone against both HeLa and human adenocarcinomic 
epithelial cell (A495) lines. Tests against L929 murine cells 
demonstrated the valuably familiar trait of reduced 
cytotoxicity of vesicle-included drugs over the free 
anticancer agents. 
 
4.4. Glycoclusters 
Bacterial adhesion to host cells is the first stage of infection 
and is associated with weak but highly specific interactions 
between the two. One key mechanism is for adhesin proteins 
to interact with monosaccharides found on cell surfaces.
[79]
 
To disrupt adhesion, and also to inhibit biofilm formation, 
compounds containing several sugars, often linked to rigid 
macrocycles, have been found to be more effective than 
those with a single sugar.
[80]
 This multivalent approach has 
been applied to pillar[5]arenes (Figure 10), predominantly 
through click chemistry, to introduce five or ten sugar 
termini. 
The Nierengarten group reported the attachment of ten 
acetylated mannose groups to pillar[5]arene by triazole 
linkers formed during the click reaction between the azido-
functionalised pillar[5]arene and the acetylated mannose 
derivative.
[81] 
The product was subsequently deacetylated to 
give 42. Haemagglutination assays with the pillar[5]arene 
and an acyclic control showed that an almost sevenfold 
enhancement in inhibition due to the presence of the 
glycocluster. Later work on the same compound found that 
it showed some inhibition against a bacterial liposaccharide 
heptosyltransferase, WaaC, involved in lipopolysaccharide 
biosynthesis.
[82]
 A month after Nierengarten’s report, Huang 
and co-workers published the synthesis of galactose-
appended 43 and asymmetric derivative 44.
[83] 
No cellular 
agglutination was observed for the symmetric pillar[5]arene, 
or an acyclic control, but the asymmetric derivative 
appeared to facilitate bacterial adhesion. 
Imberty, Vidal and colleagues also investigated the 
effects of asymmetric 45 and 46 with galactose or fucose 
termini and 47 incorporating a triethylene glycol spacer 
between the triazole and galactose.
[84] 
LecA, a bacterial 
lectin from Pseudomonas aeuruginosa, was treated with 45 
and 47; the longer chain derivative displayed a much lower 
IC50, in the micromolar range, and minimum inhibitory 
concentration. This was shown to be due to the latter’s 
ability to interact with five lectin monomers whereas the 
former was sterically crowded, due to short linkers between 
Running title 
 11 
the sugars and the macrocycle, and could only interact with 
three monomers. Nierengarten and colleagues investigated 
the effects of increasing the numbers of sugars by 
incorporating substituents with two monosaccharides.
[85]  
Fucose derivative 48 gave an IC50 value in the picomolar 
range against the lectin BambL from Burkholderia 
ambifaria. In an attempt to incorporate both fucose and 
galactose termini, the Nierengarten group prepared a number 
of rotaxanes from 49 and an alkyl thread terminating in 
either fucose or galactose.
[86] 
The combination of ten 
galcatose units and a difucose thread was highly effective 
against both LecA and LecB as it contains complementary 
sugars to both lectins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Pillar[n]arene glycoclusters 42 – 49. 
Pei and co-workers exploited the inclusion properties of 
43 by threading the macrocycle onto 
propyldisulfonylpyridine groups affixed to cerium oxide 
nanorods.
[87]
 To apply this material in a therapeutic mode, 
the nanorods were first immersed in a solution of DOX·HCl 
before the capping pillar[5]arenes were added. The nanorods 
were added to HepG2 whereupon endogenous glutathione 
cleaved the alkyldisulfonyl bond and released both the 
pillar[5]arenes and the drug. In the absence of the 
pillar[5]arene the cytotoxicity was lower due to the lack of 
targeting by the galactose termini. 
 
4.5. Towards therapeutic pillar[5]arenes 
It has already been shown how pillar[n]arenes can be used to 
bind and solubilise drugs or form nanospheres capable of 
releasing them in a controlled manner under conditions 
found in in the microenvironment around cancerous cells. 
Detection of key biomolecules, from simple amino acids 
through to proteins, has also been evidenced. Pillar[n]arene 
research is now starting to exploit the chemistry-biology 
interface to the point where its impact in medicine is now 
being felt as can be seen from the following examples. 
 
 
Figure 11. Therapeutic pillar[n]arenes 50 – 53. 
Yu and colleagues used 4c to bind choline derivatives 
and found that it could inhibit acetylcholine hydrolysis.
[88]
 
As reduced acetylcholine levels are associated with 
Alzheimer’s disease, pillar[n]arenes have the potential to 
deliver the neurotransmitter as a treatment for Alzheimer’s-
related memory loss. 
The Huang group has shown that 12 binds ATP strongly 
in the presence of similar chemical species.
[89] 
Delivering the 
pillar[6]arene as part of a micelle composed of a 
polyethylene glycol-folic acid co-polymer and filled with 
DOX to ovarian cancer (MCF-7/ADR) cells resulted in 
greater drug efficacy. The authors proposed that 12 removes 
ATP thus inhibiting the effect of the ATP-dependent efflux 
pump which would otherwise all ow the drug to escape and, 
in doing so, suggest a novel approach to tackling multidrug 
resistance. 
Zhang and colleagues prepared 50 and a pyridinium-
terminated porphyrin derivative bearing a disulfide bond 
which formed micelles in aqueous solution.
[90] 
The presence 
of glutathione monoethyl ester in an acidic environment led 
to the release of the sensitising porphyrin. Irradiation at 420 
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nm for 10 minutes resulted in the viability of A549 cells 
dropping to 20% as a consequence of locally generated 
cytotoxic singlet oxygen. The group subsequently used a 
similar system to deliver a photosensitising porphyrin that 
accumulated in the mitochondria.
[91]
 When mixed with 4a 
the porphyrin’s trimethyl ammonium terminus formed a 
pseudorotaxane with the macrocycle which self-assembled 
into micelles. Confocal laser scanning microscopy of A549 
cells following treatment with the micelles revealed 
localisation in the mitochondria and irradiation induced 
oxidative damage to the mitochondria leading to cell death. 
Tang, Huang and colleagues have applied results from 
controlled release systems to hollow mesoporous 
nanoparticles (HMNPs) through surface modification with 
diaminoalkanes which protonate below pH 7.
[92] 
The silica 
HMNPs were of the order of 200 nm in diameter with pores 
of 3 nm and incorporated magnesium so that they 
biodegrade in days at pH 4.5 to avoid potentially harmful 
aggregation of silica particles. The surface modified 
HMNPs were loaded with DOX and 4c. At low pH the 
pillar[5]arene was in the acid form and the surface of the 
HMNPs positively charged leading to disassembly and drug 
release. Solutions injected into mice with Lewis lung 
carcinoma tumours resulted in inhibition of tumour growth 
after 18 days, an outcome which was significantly better 
than DOX alone. Behavioural and blood tests on treated 
mice over 15 days revealed no adverse effects from the 
HMNPs . 
The inhibition of biofilm formation is becoming an 
important goal in the fight against disease as these 
communities of microbes, held together by an extracellular 
matrix, have far greater antibiotic resistance than isolated 
cells. The disrupting abilities of charged pillar[n]arenes have 
been exploited by the Cohen group which produced a range 
of quaternary ammonium, imidazolium and phosphonium 
derivatives, e.g. 11, 36, 51 and 52, and tested them on a 
wide range of bacterial biofilms.
[93] 
Pillar[5]arenes with 
quaternary ammonium or imidazolium groups inhibited 
assembly of biofilms formed by several Gram-positive 
pathogens including methicillin-resistant S. aureus 33592 
and Enterococcus faecalis.
[94]
 Compounds 51 and 52 were 
found to have similar activities down to submicromolar 
concentrations and, in many cases, the compounds did not 
cause cell death, nor were they toxic to mammalian cells. By 
way of contrast the monomers were only inhibitory in the 
millimolar range. The most effective compound, however, 
was found to be pillar[6]arene, 53. 
5. Summary and outlook 
The examples given above demonstrate the range of 
biomimetic and therapeutic possibilities for pillar[n]arenes. 
While artificial analogues of ion channels or enzymes are of 
interest, it would appear that detection and drug release will 
become the main areas for exploitation. To date 
pillar[n]arenes, particularly their carboxylate salts, can 
improve solubility and bioavailablility of drug molecules. 
Consequently, controlled release of drugs is an area of great 
promise. Although this has largely focused on doxorubicin it 
is clear that other drugs could be delivered in the same 
manner. The eventual move from research laboratory to the 
clinic should be substantially simplified due to the ease of 
synthesising 4a, 5a and their salts. Another area that is 
gaining in importance is the inhibition of biofilms which are 
responsible for both fouling of implants and increased 
bacterial resistance. Here too, pillar[n]arenes are having an 
impact. Finally, the molecular recognition properties of the 
pillar[n]arenes’ cavities are being harnessed to detect a 
range of analytes, from metal cations to cytochromes. 
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